Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7625975 | 0.86 | NPC1 (0.54) | NPC1RAB9AHTTSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL30496701 | 0.83 | NPC1 (0.51) | NPC1RAB9AHTTSMN1; SMN2LMNA | |
| SCHEMBL10310269 | 0.81 | TAAR1 (0.55) | NPC1RAB9AHTTSMN1; SMN2LMNA | |
| SCHEMBL625881 | 0.81 | NPC1 (0.72) | NPC1RAB9AHTTSMN1; SMN2MEN1 | |
| SCHEMBL8954327 | 0.81 | NPC1 (0.61) | NPC1RAB9AHTTSMN1; SMN2LMNA | |
| SCHEMBL15928202 | 0.81 | NPC1 (0.61) | NPC1RAB9AHTTSMN1; SMN2LMNA | |
| SCHEMBL5068038 | 0.81 | NPC1 (0.61) | NPC1RAB9AHTTSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL1623303 | 0.80 | TAAR1 (0.53) | NPC1RAB9AHTTSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL4797245 | 0.79 | NPC1 (0.59) | NPC1RAB9AHTTSMN1; SMN2LMNA | |
| SCHEMBL8488364 | 0.78 | HPGD (0.46) | NPC1RAB9AALDH1A1PKMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | claimed |
| EP-1917244-A2 | HETARYL-SUBSTITUTED GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5-RECEPTORS | Abbott GmbH & Co. KG (DE) | 2008-05-07 | — | — | EP | claimed |
| WO-2007022964-A2 | HETARYL-SUBSTITUTED GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5-RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2007-03-01 | — | — | WO | claimed |
| CN-111848494-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-111848494-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| WO-2009087395-A1 | WEIGHT REDUCING COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009087395-A1 | WEIGHT REDUCING COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2009-07-16 | — | — | WO | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| WO-2007062222-A2 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | NPC1 4461/4885RAB9A 530/4885HTT 4772/4885 |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | NPC1 1592/4885RAB9A 2328/4885HTT 399/4885 |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | NPC1 4461/4885RAB9A 530/4885HTT 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.